LBIO News Alert Lion Biotechnologies Inc. (LBIO) 6.8100 09/21/2014
Post# of 273311
Posted On: 09/21/2014 9:43:50 AM
Lion Biotechnologies Inc. (LBIO) 6.8100 $LBIO
Lion Biotechnologies to Present at the Rodman & Renshaw 16th Annual Global Investment Conference
GlobeNewswire - Fri Sep 05, 8:46AM CDT
Lion Biotechnologies, Inc. (OTCQB:LBIO), a biotechnology company focused on the development and commercialization of novel cancer immunotherapies based on tumor-infiltrating lymphocytes (TILs), today announced that Chief Executive Officer Manish Singh, Ph.D., will present at the Rodman & Renshaw 16th Annual Global Investment Conference on Tuesday, September 9, 2014, at 9:35 a.m. Eastern in Holmes II Salon (4th floor). The conference is being held at The New York Palace Hotel from September 8-10, 2014.
Lion Biotechnologies Names Elma Hawkins President and Chief Operating Officer
GlobeNewswire - Wed Aug 20, 3:13PM CDT
Lion Biotechnologies, Inc. (OTCBB:LBIO), a biotechnology company that is developing novel cancer immunotherapies based on tumor infiltrating lymphocytes (TILs), today announced that it has hired Elma Hawkins, PhD, MBA, to serve as president and chief operating officer. Her appointment is effective immediately.
Lion Biotechnologies' Chief Scientific Officer to Present at Immunotherapies and Vaccines Summit
GlobeNewswire - Mon Aug 11, 7:02AM CDT
Lion Biotechnologies, Inc. (OTCQB:LBIO), a biotechnology company that is developing novel cancer immunotherapies based on tumor infiltrating lymphocytes (TILs), today announced that Laszlo Radvanyi, PhD, the company's chief scientific officer (CSO), will present at the ninth annual Immunotherapies and Vaccines Summit (ImVacS), to be held August 11-14 in Boston, MA.
Lion Biotechnologies Enters Clinical Trial Grant Agreement With Moffitt Cancer Center
GlobeNewswire - Wed Jul 30, 7:00AM CDT
Lion Biotechnologies, Inc. (OTCQB:LBIO), a biotechnology company that is developing novel cancer immunotherapies based on tumor infiltrating lymphocytes (TILs), today announced that it has entered into a clinical trial grant agreement with Moffitt Cancer Center to expand an ongoing Phase 1 study of TILs combined with ipilimumab in patients with metastatic melanoma.
Lion Biotechnologies Announces Exclusive License Agreement With Moffitt Cancer Center
GlobeNewswire - Fri Jul 25, 7:00AM CDT
Lion Biotechnologies, Inc. (OTCQB:LBIO), a biotechnology company that is developing novel cancer immunotherapies based on tumor infiltrating lymphocytes (TILs), today announced that it has entered into an exclusive, worldwide license agreement with Moffitt Cancer Center.
Lion Biotechnologies Leases New Research Laboratory
GlobeNewswire - Wed Jul 23, 7:00AM CDT
Lion Biotechnologies, Inc. (OTCQB:LBIO), a biotechnology company that is developing novel cancer immunotherapies based on tumor infiltrating lymphocytes (TILs), today announced that it has entered into a five-year lease agreement for a new research laboratory at University of South Florida Research Park in Tampa, FL.
Lion Biotechnologies Appoints Dr. Laszlo Radvanyi as Chief Scientific Officer
GlobeNewswire - Mon Jun 23, 7:01AM CDT
Lion Biotechnologies, Inc. (OTCQB:LBIO), a biotechnology company that is developing novel cancer immunotherapies based on tumor infiltrating lymphocytes (TILs), today announced that it has appointed Laszlo Radvanyi, PhD, as its chief scientific officer (CSO).
Lion Biotechnologies to Present at the 4th Annual Cancer Immunotherapy Conference
GlobeNewswire - Mon Mar 24, 7:00AM CDT
Lion Biotechnologies, Inc. (OTCQB:LBIO), a biotechnology company focused on the development and commercialization of novel cancer immunotherapies based on tumor-infiltrating lymphocytes (TILs), today announced that Chief Executive Officer Manish Singh, Ph.D., will be presenting at the 4th Annual Cancer Immunotherapy Conference at the New York Academy of Medicine in New York City. The presentation is scheduled for Thursday, March 27, 2014, at 9:00 am Eastern Time.
Lion Biotechnologies to Present at the BioCentury Future Leaders Conference
GlobeNewswire - Fri Mar 21, 7:00AM CDT
Lion Biotechnologies, Inc. (OTCQB:LBIO), a biotechnology company focused on the development and commercialization of novel cancer immunotherapies based on tumor-infiltrating lymphocytes (TILs), today announced that Chief Executive Officer Manish Singh, Ph.D., will be presenting at the BioCentury Future Leaders in the Biotech Industry Conference at the Millennium Broadway Hotel in New York City. The presentation is scheduled for Friday, March 28, 2014, at 2:30 pm Eastern Time.
Lion Biotechnologies to Present at the 26th Annual ROTH Conference
GlobeNewswire - Tue Mar 04, 7:01AM CST
Lion Biotechnologies, Inc. (OTCQB:LBIO) announced that Chief Executive Officer Manish Singh, Ph.D., will present at the 26 Annual ROTH Conference on Tuesday, March 11, 2014, at 1:00 p.m. Pacific in Salon 5. The conference is being held at The Ritz Carlton in Dana Point, California, from March 9-12, 2014.
Lion Biotechnologies Issues Letter to Shareholders
GlobeNewswire - Mon Feb 03, 7:00AM CST
Lion Biotechnologies, Inc. (OTCQB:LBIO) announced that Chairman and CEO, Manish Singh, Ph.D., has issued the following letter to the shareholders.
Lion Biotechnologies' CEO Manish Singh, Ph.D., to Chair Opening Session at Phacilitate's Immunotherapy Forum on January 27
Business Wire - Fri Jan 24, 7:00AM CST
Lion Biotechnologies, Inc. (OTCQB: LBIO) announced that Chief Executive Officer Manish Singh, Ph.D., will preside over the introductory session of the Phacilitate Immunotherapy Forum on Monday, January 27, 2014. Titled "Overviewing key trends in immunotherapy R&D investment, collaboration and pipeline strategies," the session will include presentations by executives from biotechnology and pharmaceutical companies, and a panel discussion with life science industry and venture capital executives.
Worldwide Engineered T-Cell Receptor in Fusion Proteins, Antibodies & Cells Report
M2 - Mon Jan 20, 9:48AM CST
Research and Markets (http://www.researchandmarkets.com/research/fh839h/the_engineered) has announced the addition of the "Worldwide Engineered T-Cell Receptor in Fusion Proteins, Antibodies & Cells Report" report to their offering. This report entitled 'The Engineered T-Cell Receptor in Fusion Proteins, Antibodies & Cells: Emerging Opportunities for the Biopharmaceutical Industry' describes chances and pitfalls in exploiting the opportunities which offers the engineered T-cell receptor as integral part of fusion proteins, antibodies and cellular products. The key success factors are highlighted, the technical challenges described and solutions presented. Benefits from the report: - Identify players in the field, from industry and academia; - Find out which TCR technologies are valued by Big Pharma and Biotech; - Understand the value of intracellular antigens targeted by the TCR; - Recognize the challenges of TCR-based therapeutics and their solutions; - Learn which TCR-based therapeutics are attractive for partnering; - Find out which TCR therapeutic approaches are not yet tapped. Key Topics Covered: 1. Executive Summary 2. Introduction 3. The T-Cell Receptor 4. TCR Fusion Proteins 5. TCR-Like (TCRL) Antibodies 6. TCR-Transfected T-Cells 7. Artificial TCR T-Cells: Chimeric Antigen Receptor (CAR) T-Cells 8. Tumor-Infiltrating Lymphocytes (TILs) 9. Opportunity Analysis for TCR-based Products and Technologies 10. References 11. Corporate R&D Pipelines Companies Mentioned - Adaptimmune - Altor Bioscience - Immunocore - Lion Biotechnologies For more information visit http://www.researchandmarkets.com/research/fh...engineered
Lion Biotechnologies to Present at the Biotech Showcase on January 15
Business Wire - Mon Jan 13, 7:00AM CST
Lion Biotechnologies, Inc. (OTCQB: LBIO) announced that Chief Executive Officer Manish Singh, Ph.D., will present at the Biotech Showcase on Wednesday, January 15, 2014, at 11:00 a.m. Pacific. The conference is being held at the Parc 55 Wyndham Union Square Hotel in San Francisco. Dr. Singh's presentation will be in Mission Room II.
Lion Biotechnologies Appoints James Bender, Ph.D., as Vice President, Product Development and Manufacturing
Business Wire - Thu Jan 09, 6:59AM CST
Lion Biotechnologies, Inc. (OTCQB: LBIO) announced the appointment of James G. Bender, Ph.D., as Vice President, Product Development and Manufacturing. Dr. Bender has more than 25 years of clinical development experience, primarily focused on cancer therapies, including tumor-infiltrating lymphocytes (TILs).
Lion Biotechnologies to Present at the Rodman & Renshaw 16th Annual Global Investment Conference
GlobeNewswire - Fri Sep 05, 8:46AM CDT
Lion Biotechnologies, Inc. (OTCQB:LBIO), a biotechnology company focused on the development and commercialization of novel cancer immunotherapies based on tumor-infiltrating lymphocytes (TILs), today announced that Chief Executive Officer Manish Singh, Ph.D., will present at the Rodman & Renshaw 16th Annual Global Investment Conference on Tuesday, September 9, 2014, at 9:35 a.m. Eastern in Holmes II Salon (4th floor). The conference is being held at The New York Palace Hotel from September 8-10, 2014.
Lion Biotechnologies Names Elma Hawkins President and Chief Operating Officer
GlobeNewswire - Wed Aug 20, 3:13PM CDT
Lion Biotechnologies, Inc. (OTCBB:LBIO), a biotechnology company that is developing novel cancer immunotherapies based on tumor infiltrating lymphocytes (TILs), today announced that it has hired Elma Hawkins, PhD, MBA, to serve as president and chief operating officer. Her appointment is effective immediately.
Lion Biotechnologies' Chief Scientific Officer to Present at Immunotherapies and Vaccines Summit
GlobeNewswire - Mon Aug 11, 7:02AM CDT
Lion Biotechnologies, Inc. (OTCQB:LBIO), a biotechnology company that is developing novel cancer immunotherapies based on tumor infiltrating lymphocytes (TILs), today announced that Laszlo Radvanyi, PhD, the company's chief scientific officer (CSO), will present at the ninth annual Immunotherapies and Vaccines Summit (ImVacS), to be held August 11-14 in Boston, MA.
Lion Biotechnologies Enters Clinical Trial Grant Agreement With Moffitt Cancer Center
GlobeNewswire - Wed Jul 30, 7:00AM CDT
Lion Biotechnologies, Inc. (OTCQB:LBIO), a biotechnology company that is developing novel cancer immunotherapies based on tumor infiltrating lymphocytes (TILs), today announced that it has entered into a clinical trial grant agreement with Moffitt Cancer Center to expand an ongoing Phase 1 study of TILs combined with ipilimumab in patients with metastatic melanoma.
Lion Biotechnologies Announces Exclusive License Agreement With Moffitt Cancer Center
GlobeNewswire - Fri Jul 25, 7:00AM CDT
Lion Biotechnologies, Inc. (OTCQB:LBIO), a biotechnology company that is developing novel cancer immunotherapies based on tumor infiltrating lymphocytes (TILs), today announced that it has entered into an exclusive, worldwide license agreement with Moffitt Cancer Center.
Lion Biotechnologies Leases New Research Laboratory
GlobeNewswire - Wed Jul 23, 7:00AM CDT
Lion Biotechnologies, Inc. (OTCQB:LBIO), a biotechnology company that is developing novel cancer immunotherapies based on tumor infiltrating lymphocytes (TILs), today announced that it has entered into a five-year lease agreement for a new research laboratory at University of South Florida Research Park in Tampa, FL.
Lion Biotechnologies Appoints Dr. Laszlo Radvanyi as Chief Scientific Officer
GlobeNewswire - Mon Jun 23, 7:01AM CDT
Lion Biotechnologies, Inc. (OTCQB:LBIO), a biotechnology company that is developing novel cancer immunotherapies based on tumor infiltrating lymphocytes (TILs), today announced that it has appointed Laszlo Radvanyi, PhD, as its chief scientific officer (CSO).
Lion Biotechnologies to Present at the 4th Annual Cancer Immunotherapy Conference
GlobeNewswire - Mon Mar 24, 7:00AM CDT
Lion Biotechnologies, Inc. (OTCQB:LBIO), a biotechnology company focused on the development and commercialization of novel cancer immunotherapies based on tumor-infiltrating lymphocytes (TILs), today announced that Chief Executive Officer Manish Singh, Ph.D., will be presenting at the 4th Annual Cancer Immunotherapy Conference at the New York Academy of Medicine in New York City. The presentation is scheduled for Thursday, March 27, 2014, at 9:00 am Eastern Time.
Lion Biotechnologies to Present at the BioCentury Future Leaders Conference
GlobeNewswire - Fri Mar 21, 7:00AM CDT
Lion Biotechnologies, Inc. (OTCQB:LBIO), a biotechnology company focused on the development and commercialization of novel cancer immunotherapies based on tumor-infiltrating lymphocytes (TILs), today announced that Chief Executive Officer Manish Singh, Ph.D., will be presenting at the BioCentury Future Leaders in the Biotech Industry Conference at the Millennium Broadway Hotel in New York City. The presentation is scheduled for Friday, March 28, 2014, at 2:30 pm Eastern Time.
Lion Biotechnologies to Present at the 26th Annual ROTH Conference
GlobeNewswire - Tue Mar 04, 7:01AM CST
Lion Biotechnologies, Inc. (OTCQB:LBIO) announced that Chief Executive Officer Manish Singh, Ph.D., will present at the 26 Annual ROTH Conference on Tuesday, March 11, 2014, at 1:00 p.m. Pacific in Salon 5. The conference is being held at The Ritz Carlton in Dana Point, California, from March 9-12, 2014.
Lion Biotechnologies Issues Letter to Shareholders
GlobeNewswire - Mon Feb 03, 7:00AM CST
Lion Biotechnologies, Inc. (OTCQB:LBIO) announced that Chairman and CEO, Manish Singh, Ph.D., has issued the following letter to the shareholders.
Lion Biotechnologies' CEO Manish Singh, Ph.D., to Chair Opening Session at Phacilitate's Immunotherapy Forum on January 27
Business Wire - Fri Jan 24, 7:00AM CST
Lion Biotechnologies, Inc. (OTCQB: LBIO) announced that Chief Executive Officer Manish Singh, Ph.D., will preside over the introductory session of the Phacilitate Immunotherapy Forum on Monday, January 27, 2014. Titled "Overviewing key trends in immunotherapy R&D investment, collaboration and pipeline strategies," the session will include presentations by executives from biotechnology and pharmaceutical companies, and a panel discussion with life science industry and venture capital executives.
Worldwide Engineered T-Cell Receptor in Fusion Proteins, Antibodies & Cells Report
M2 - Mon Jan 20, 9:48AM CST
Research and Markets (http://www.researchandmarkets.com/research/fh839h/the_engineered) has announced the addition of the "Worldwide Engineered T-Cell Receptor in Fusion Proteins, Antibodies & Cells Report" report to their offering. This report entitled 'The Engineered T-Cell Receptor in Fusion Proteins, Antibodies & Cells: Emerging Opportunities for the Biopharmaceutical Industry' describes chances and pitfalls in exploiting the opportunities which offers the engineered T-cell receptor as integral part of fusion proteins, antibodies and cellular products. The key success factors are highlighted, the technical challenges described and solutions presented. Benefits from the report: - Identify players in the field, from industry and academia; - Find out which TCR technologies are valued by Big Pharma and Biotech; - Understand the value of intracellular antigens targeted by the TCR; - Recognize the challenges of TCR-based therapeutics and their solutions; - Learn which TCR-based therapeutics are attractive for partnering; - Find out which TCR therapeutic approaches are not yet tapped. Key Topics Covered: 1. Executive Summary 2. Introduction 3. The T-Cell Receptor 4. TCR Fusion Proteins 5. TCR-Like (TCRL) Antibodies 6. TCR-Transfected T-Cells 7. Artificial TCR T-Cells: Chimeric Antigen Receptor (CAR) T-Cells 8. Tumor-Infiltrating Lymphocytes (TILs) 9. Opportunity Analysis for TCR-based Products and Technologies 10. References 11. Corporate R&D Pipelines Companies Mentioned - Adaptimmune - Altor Bioscience - Immunocore - Lion Biotechnologies For more information visit http://www.researchandmarkets.com/research/fh...engineered
Lion Biotechnologies to Present at the Biotech Showcase on January 15
Business Wire - Mon Jan 13, 7:00AM CST
Lion Biotechnologies, Inc. (OTCQB: LBIO) announced that Chief Executive Officer Manish Singh, Ph.D., will present at the Biotech Showcase on Wednesday, January 15, 2014, at 11:00 a.m. Pacific. The conference is being held at the Parc 55 Wyndham Union Square Hotel in San Francisco. Dr. Singh's presentation will be in Mission Room II.
Lion Biotechnologies Appoints James Bender, Ph.D., as Vice President, Product Development and Manufacturing
Business Wire - Thu Jan 09, 6:59AM CST
Lion Biotechnologies, Inc. (OTCQB: LBIO) announced the appointment of James G. Bender, Ph.D., as Vice President, Product Development and Manufacturing. Dr. Bender has more than 25 years of clinical development experience, primarily focused on cancer therapies, including tumor-infiltrating lymphocytes (TILs).
(0)
(0)